Clinical Cellular Therapeutics Accelerate Clot Formation
Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimula...
Saved in:
| Published in | Stem cells translational medicine Vol. 7; no. 10; pp. 731 - 739 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hoboken, USA
John Wiley & Sons, Inc
01.10.2018
Oxford University Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2157-6564 2157-6580 2157-6580 |
| DOI | 10.1002/sctm.18-0015 |
Cover
| Abstract | Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi‐potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence‐activated cell sorting (FACS) separated samples into high‐ and low‐TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High‐TF expressing cells decreased clotting time more than low‐TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion. Stem Cells Translational Medicine 2018;7:731–739
Clinical cellular therapeutics express different amounts of tissue factor. As their tissue factor load increases, time to clot formation relative to control decreases. Adipose MSCs express high levels of tissue factor and accelerate clot formation the most. Variation in tissue factor load and relative decrease in clotting time are expressed as standard error of the mean. |
|---|---|
| AbstractList | Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi‐potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence‐activated cell sorting (FACS) separated samples into high‐ and low‐TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High‐TF expressing cells decreased clotting time more than low‐TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion. Stem Cells Translational Medicine 2018;7:731–739 Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi-potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence-activated cell sorting (FACS) separated samples into high- and low-TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High-TF expressing cells decreased clotting time more than low-TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion. Stem Cells Translational Medicine 2018;7:731-739. Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi-potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence-activated cell sorting (FACS) separated samples into high- and low-TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High-TF expressing cells decreased clotting time more than low-TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion. Stem Cells Translational Medicine 2018;7:731-739.Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi-potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence-activated cell sorting (FACS) separated samples into high- and low-TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High-TF expressing cells decreased clotting time more than low-TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion. Stem Cells Translational Medicine 2018;7:731-739. Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi‐potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence‐activated cell sorting (FACS) separated samples into high‐ and low‐TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High‐TF expressing cells decreased clotting time more than low‐TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion. Stem Cells Translational Medicine 2018;7:731–739 Clinical cellular therapeutics express different amounts of tissue factor. As their tissue factor load increases, time to clot formation relative to control decreases. Adipose MSCs express high levels of tissue factor and accelerate clot formation the most. Variation in tissue factor load and relative decrease in clotting time are expressed as standard error of the mean. Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi-potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence-activated cell sorting (FACS) separated samples into high- and low-TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High-TF expressing cells decreased clotting time more than low-TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion. Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial infarction, and improving functional recovery after stroke. However, most clinically available cell lines express tissue factor (TF) which stimulates coagulation. We sought to define the degree of procoagulant activity of CCTs as related to TF expression. CCT samples from bone marrow, adipose, amniotic fluid, umbilical cord, multi‐potent adult progenitor cell donors, and bone marrow mononuclear cells were tested. TF expression and phenotype were quantified using flow cytometry. Procoagulant activity of the CCTs was measured in vitro with thromboelastography and calibrated thrombogram. Fluorescence‐activated cell sorting (FACS) separated samples into high‐ and low‐TF expressing populations to isolate the contribution of TF to coagulation. A TF neutralizing antibody was incubated with samples to demonstrate loss of procoagulant function. All CCTs tested expressed procoagulant activity that correlated with expression of tissue factor. Time to clot and thrombin formation decreased with increasing TF expression. High‐TF expressing cells decreased clotting time more than low‐TF expressing cells when isolated from a single donor using FACS. A TF neutralizing antibody restored clotting time to control values in some, but not all, CCT samples. CCTs demonstrate wide variability in procoagulant activity related to TF expression. Time to clot and thrombin formation decreases as TF load increases and this procoagulant effect is neutralized by a TF blocking antibody. Clinical trials using CCTs are in progress and TF expression may emerge as a safety release criterion. S tem C ells T ranslational M edicine 2018;7:731–739 |
| Audience | Academic |
| Author | Toledano‐Furman, Naama E. Wade, Charles E. Olson, Scott D. Gill, Brijesh S. Wang, Yao‐Wei Cox, Charles S. George, Mitchell J. Prabhakara, Karthik |
| AuthorAffiliation | 1 Department of Surgery McGovern Medical School at The University of Texas Health Science Center Houston Texas USA 2 Department of Pediatric Surgery McGovern Medical School at The University of Texas Health Science Center Houston Texas USA |
| AuthorAffiliation_xml | – name: 2 Department of Pediatric Surgery McGovern Medical School at The University of Texas Health Science Center Houston Texas USA – name: 1 Department of Surgery McGovern Medical School at The University of Texas Health Science Center Houston Texas USA |
| Author_xml | – sequence: 1 givenname: Mitchell J. orcidid: 0000-0003-1668-821X surname: George fullname: George, Mitchell J. organization: McGovern Medical School at The University of Texas Health Science Center – sequence: 2 givenname: Karthik surname: Prabhakara fullname: Prabhakara, Karthik organization: McGovern Medical School at The University of Texas Health Science Center – sequence: 3 givenname: Naama E. surname: Toledano‐Furman fullname: Toledano‐Furman, Naama E. organization: McGovern Medical School at The University of Texas Health Science Center – sequence: 4 givenname: Yao‐Wei surname: Wang fullname: Wang, Yao‐Wei organization: McGovern Medical School at The University of Texas Health Science Center – sequence: 5 givenname: Brijesh S. surname: Gill fullname: Gill, Brijesh S. organization: McGovern Medical School at The University of Texas Health Science Center – sequence: 6 givenname: Charles E. surname: Wade fullname: Wade, Charles E. organization: McGovern Medical School at The University of Texas Health Science Center – sequence: 7 givenname: Scott D. orcidid: 0000-0001-8032-3755 surname: Olson fullname: Olson, Scott D. organization: McGovern Medical School at The University of Texas Health Science Center – sequence: 8 givenname: Charles S. surname: Cox fullname: Cox, Charles S. email: charles.s.cox@uth.tmc.edu organization: McGovern Medical School at The University of Texas Health Science Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30070065$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kc9vFSEQx4mpsbX25tls4sVDtwKz_NiLycvGqkkTDz7PhOVBS8PCE3Zr-t_L62urNlEuMOEz3_nOzEt0EFO0CL0m-IxgTN8XM09nRLYYE_YMHVHCRMuZxAePb94dopNSrnE9vOc9xS_QIWAsasiOkByCj97o0Aw2hCXo3KyvbNZbu8zelGZljA01nm0zhDQ35ylPevYpvkLPnQ7Fntzfx-j7-cf18Lm9-Prpy7C6aE0nO9LCxoqR9SCBaMYYcRrk6LQZhQTnqOEcgPAequeNY3S0AtzIZd87boSBEY7Rh73udhknuzE2zlkHtc1-0vlWJe3V3z_RX6nLdKM4kZwKqALv7gVy-rHYMqvJl9pU0NGmpSiKJcU9Y5hX9O0T9DotOdb2FK02OyKq19_UpQ5W-ehSrWt2omolgAne9byr1Js_fT8afhh9BegeMDmVkq1Txs93o61yPiiC1W7FardiRaTarbgmnT5JetD9Bw57_KcP9va_rPo2rIFQ6Aj8AtPUteY |
| CitedBy_id | crossref_primary_10_1002_stem_3320 crossref_primary_10_1002_sctm_18_0194 crossref_primary_10_1186_s13287_019_1391_x crossref_primary_10_3389_fimmu_2020_02029 crossref_primary_10_1016_j_joca_2023_12_007 crossref_primary_10_1126_sciadv_aba6884 crossref_primary_10_3389_fimmu_2019_01645 crossref_primary_10_1002_sctm_19_0206 crossref_primary_10_1111_trf_15187 crossref_primary_10_3390_ijms25136973 crossref_primary_10_1186_s41256_022_00251_5 crossref_primary_10_1186_s13287_020_01855_9 crossref_primary_10_1186_s40635_024_00596_w crossref_primary_10_3389_fimmu_2020_583017 crossref_primary_10_3390_ijms22084178 crossref_primary_10_1097_TP_0000000000003765 crossref_primary_10_1111_sji_13267 crossref_primary_10_1002_stem_3354 crossref_primary_10_1186_s12967_020_02380_2 crossref_primary_10_3389_fcell_2021_661532 crossref_primary_10_3389_fimmu_2019_01151 crossref_primary_10_3390_ijms231810393 crossref_primary_10_3389_fcell_2022_883996 crossref_primary_10_1007_s12015_020_10086_7 crossref_primary_10_1016_j_biopha_2022_112920 crossref_primary_10_3389_fcell_2021_717913 crossref_primary_10_3389_fimmu_2019_01952 crossref_primary_10_1016_j_molmed_2018_12_006 crossref_primary_10_1093_stcltm_szab005 crossref_primary_10_3389_fimmu_2020_01091 crossref_primary_10_1016_j_jcyt_2019_05_003 crossref_primary_10_1186_s13287_023_03582_3 crossref_primary_10_1016_j_cellimm_2023_104771 crossref_primary_10_3390_ijms24119216 crossref_primary_10_1080_09537104_2020_1856356 crossref_primary_10_3390_cells8080846 crossref_primary_10_1097_TA_0000000000002743 crossref_primary_10_1016_j_jcyt_2023_04_013 crossref_primary_10_1016_j_isci_2022_104822 crossref_primary_10_3389_fimmu_2022_874698 crossref_primary_10_1016_j_jcyt_2023_11_010 crossref_primary_10_3389_fcell_2022_902677 crossref_primary_10_1002_sctm_20_0454 crossref_primary_10_3390_cells11172686 crossref_primary_10_3390_ijms242316920 crossref_primary_10_1002_ibra_12095 crossref_primary_10_3389_fimmu_2022_839844 crossref_primary_10_1055_s_0040_1713422 crossref_primary_10_3389_fimmu_2020_01306 crossref_primary_10_1007_s12015_021_10192_0 crossref_primary_10_3389_fmed_2021_728496 crossref_primary_10_1371_journal_pone_0251601 crossref_primary_10_1111_trf_17454 crossref_primary_10_4252_wjsc_v15_i11_999 crossref_primary_10_1186_s12964_022_00919_y crossref_primary_10_3390_cells8101160 |
| Cites_doi | 10.1371/journal.pone.0025171 10.1097/TA.0000000000001466 10.1111/j.1747-4949.2012.00919.x 10.1046/j.1365-2362.1997.570614.x 10.1097/TA.0000000000001485 10.1002/stem.633 10.1055/s-0038-1646454 10.1371/journal.pone.0021703 10.1002/stem.2050 10.7150/thno.16911 10.1089/scd.2015.0120 10.1002/stem.1111 10.1097/TA.0b013e3182984911 10.1371/journal.pone.0007809 10.1016/S0301-472X(02)00869-X 10.1002/stem.1729 10.1016/j.bbrc.2013.05.013 10.1089/scd.2008.0253 10.1002/stem.2603 10.1126/science.290.5497.1779 10.1371/journal.pone.0042819 10.3389/fimmu.2017.00795 10.1186/s13054-014-0549-2 10.1213/01.ANE.0000149902.73689.64 10.5966/sctm.2013-0031 10.1016/j.surg.2012.06.006 10.1016/j.expneurol.2010.07.005 10.1513/pats.201012-071DW |
| ContentType | Journal Article |
| Copyright | 2018 The Authors. published by Wiley Periodicals, Inc. on behalf of AlphaMed Press 2018 The Authors. Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. COPYRIGHT 2018 Oxford University Press 2018. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2018 The Authors. S C T M published by Wiley Periodicals, Inc. on behalf of AlphaMed Press |
| Copyright_xml | – notice: 2018 The Authors. published by Wiley Periodicals, Inc. on behalf of AlphaMed Press – notice: 2018 The Authors. Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. – notice: COPYRIGHT 2018 Oxford University Press – notice: 2018. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2018 The Authors. S C T M published by Wiley Periodicals, Inc. on behalf of AlphaMed Press |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1002/sctm.18-0015 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection (subscription) ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | Cellular Therapeutics Accelerate Clot Formation |
| EISSN | 2157-6580 |
| EndPage | 739 |
| ExternalDocumentID | PMC6186273 A735764964 30070065 10_1002_sctm_18_0015 SCT312341 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States Atlanta Georgia Grand Island New York |
| GeographicLocations_xml | – name: United States – name: Atlanta Georgia – name: Grand Island New York |
| GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: T32 GM008792 |
| GroupedDBID | 0R~ 1OC 24P 53G 5RE 7X7 8FE 8FH 8FI 8FJ AAHHS AAKDD AAPXW AAVAP ABEJV ABPTD ABUWG ABXVV ACCFJ ACCMX ACXQS ADBBV ADKYN ADZMN AEEZP AENEX AEQDE AFKRA AIWBW AJAOE AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMNDL AOIJS AVUZU BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU DIK EBD EBS EJD EMOBN FYUFA GROUPED_DOAJ H13 HCIFZ HMCUK HYE HZ~ LK8 M7P O9- OK1 OVD PIMPY PQQKQ PROAC RHI ROX RPM SV3 TOX UKHRP WIN AAYXX ABGNP CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AAMMB AEFGJ AGXDD AIDQK AIDYY AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQGLB PQUKI PRINS PUEGO 7X8 5PM |
| ID | FETCH-LOGICAL-c4841-3de7b593831a5551fa38bfacb783ff2c66331693580df52be73fb6899f6c7c3b3 |
| IEDL.DBID | 7X7 |
| ISSN | 2157-6564 2157-6580 |
| IngestDate | Thu Aug 21 18:41:27 EDT 2025 Fri Sep 05 03:53:06 EDT 2025 Sat Sep 20 13:11:55 EDT 2025 Tue Jun 17 21:18:08 EDT 2025 Thu Apr 03 07:00:07 EDT 2025 Tue Jul 01 03:57:57 EDT 2025 Thu Apr 24 22:59:10 EDT 2025 Wed Jan 22 16:31:39 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | Clinical cellular therapeutics Coagulation Tissue factor |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs http://creativecommons.org/licenses/by-nc-nd/4.0 2018 The Authors. Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4841-3de7b593831a5551fa38bfacb783ff2c66331693580df52be73fb6899f6c7c3b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-8032-3755 0000-0003-1668-821X |
| OpenAccessLink | https://www.proquest.com/docview/2331417316?pq-origsite=%requestingapplication% |
| PMID | 30070065 |
| PQID | 2331417316 |
| PQPubID | 4370291 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6186273 proquest_miscellaneous_2082095506 proquest_journals_2331417316 gale_infotracmisc_A735764964 pubmed_primary_30070065 crossref_citationtrail_10_1002_sctm_18_0015 crossref_primary_10_1002_sctm_18_0015 wiley_primary_10_1002_sctm_18_0015_SCT312341 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | October 2018 |
| PublicationDateYYYYMMDD | 2018-10-01 |
| PublicationDate_xml | – month: 10 year: 2018 text: October 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Oxford |
| PublicationTitle | Stem cells translational medicine |
| PublicationTitleAlternate | Stem Cells Transl Med |
| PublicationYear | 2018 |
| Publisher | John Wiley & Sons, Inc Oxford University Press |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Oxford University Press |
| References | 2017; 83 2009; 66 2017; 7 2017; 8 2013; 2 1989; 134 2002; 30 2010; 225 2015; 33 2015; 10 1997; 27 2011; 6 2011; 8 2000; 290 2012; 30 2015; 24 1994; 388 2012; 152 2005; 100 1991; 66 2013; 435 2017; 35 2013; 75 2014; 18 2009; 4 2012; 7 2011; 29 2009; 18 2014; 32 Walker (2022022809002138600_sct312341-bib-0006) 2012; 152 Liao (2022022809002138600_sct312341-bib-0020) 2017; 7 Drake (2022022809002138600_sct312341-bib-0001) 1989; 134 Pati (2022022809002138600_sct312341-bib-0003) 2011; 6 Baygan (2022022809002138600_sct312341-bib-0021) 2017; 8 Burrows (2022022809002138600_sct312341-bib-0014) 2013; 2 Aranda (2022022809002138600_sct312341-bib-0016) 2009; 4 Van Haren (2022022809002138600_sct312341-bib-0024) 2013; 75 Roobrouck (2022022809002138600_sct312341-bib-0013) 2011; 29 Hogan (2022022809002138600_sct312341-bib-0032) 2013; 435 Stephenne (2022022809002138600_sct312341-bib-0019) 2012; 7 Moll (2022022809002138600_sct312341-bib-0007) 2015; 24 Park (2022022809002138600_sct312341-bib-0026) 2017; 83 Christy (2022022809002138600_sct312341-bib-0009) 2017; 83 Moll (2022022809002138600_sct312341-bib-0029) 2014; 32 Elliott (2022022809002138600_sct312341-bib-0023) 2015; 10 Fischer (2022022809002138600_sct312341-bib-0012) 2009; 18 Mezey (2022022809002138600_sct312341-bib-0004) 2000; 290 Boozer (2022022809002138600_sct312341-bib-0015) 2009; 4 Walker (2022022809002138600_sct312341-bib-0002) 2010; 225 Van (2022022809002138600_sct312341-bib-0022) 2009; 66 Katori (2022022809002138600_sct312341-bib-0027) 2005; 100 Ruf (2022022809002138600_sct312341-bib-0018) 1991; 66 Gleeson (2022022809002138600_sct312341-bib-0010) 2015; 33 Kota (2022022809002138600_sct312341-bib-0011) 2017; 35 Moll (2022022809002138600_sct312341-bib-0028) 2011; 6 Levi (2022022809002138600_sct312341-bib-0031) 1997; 27 Jiang (2022022809002138600_sct312341-bib-0017) 2002; 30 Weiss (2022022809002138600_sct312341-bib-0005) 2011; 8 Moll (2022022809002138600_sct312341-bib-0008) 2012; 30 Taylor (2022022809002138600_sct312341-bib-0030) 1994; 388 Hincker (2022022809002138600_sct312341-bib-0025) 2014; 18 |
| References_xml | – volume: 134 start-page: 1087 year: 1989 end-page: 1097 article-title: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis publication-title: Am J Pathol – volume: 66 start-page: 529 year: 1991 end-page: 533 article-title: An anti‐tissue factor monoclonal antibody which inhibits TF.VIIa complex is a potent anticoagulant in plasma publication-title: Thromb Haemost – volume: 32 start-page: 2430 year: 2014 end-page: 2442 article-title: Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? publication-title: Stem Cells – volume: 290 start-page: 1779 year: 2000 end-page: 1782 article-title: Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow publication-title: Science – volume: 8 start-page: 223 year: 2011 end-page: 272 article-title: Stem cells and cell therapies in lung biology and lung diseases publication-title: Proc Am Thorac Soc – volume: 10 start-page: 194 year: 2015 end-page: 201 article-title: Thromboelastography in patients with acute ischemic stroke publication-title: Int J Stroke – volume: 7 start-page: 106 year: 2017 end-page: 116 article-title: Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow‐derived mesenchymal stem cell cytotherapy publication-title: Theranostics – volume: 75 start-page: 37 year: 2013 end-page: 43 article-title: Hypercoagulability after burn injury publication-title: J Trauma Acute Care Surg – volume: 18 start-page: 683 year: 2009 end-page: 692 article-title: Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first‐pass effect publication-title: Stem Cells Dev – volume: 29 start-page: 871 year: 2011 end-page: 882 article-title: Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions publication-title: Stem Cells – volume: 4 start-page: 17 year: 2009 end-page: 28 article-title: Global characterization and genomic stability of human multistem, a multipotent adult progenitor cell publication-title: J Stem Cells – volume: 388 start-page: 175 year: 1994 end-page: 194 article-title: Studies on the inflammatory‐coagulant axis in the baboon response to : Regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor publication-title: Prog Clin Biol Res – volume: 18 start-page: 549 year: 2014 article-title: Rotational thromboelastometry predicts thromboembolic complications after major non‐cardiac surgery publication-title: Crit Care – volume: 4 start-page: e7809 year: 2009 article-title: Epigenetic signatures associated with different levels of differentiation potential in human stem cells publication-title: PLoS One – volume: 6 start-page: e25171 year: 2011 article-title: Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock publication-title: PLoS One – volume: 83 start-page: S164 year: 2017 end-page: S169 article-title: Pro‐coagulant activity of human mesenchymal stem cells publication-title: J Trauma Acute Care Surg – volume: 2 start-page: 745 year: 2013 end-page: 757 article-title: Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis publication-title: Stem Cells Translational Medicine – volume: 100 start-page: 1781 year: 2005 end-page: 1785 article-title: The effects of platelet count on clot retraction and tissue plasminogen activator‐induced fibrinolysis on thrombelastography publication-title: Anesth Analg – volume: 435 start-page: 574 year: 2013 end-page: 579 article-title: Impact of mesenchymal stem cell secreted PAI‐1 on colon cancer cell migration and proliferation publication-title: Biochem Biophys Res Commun – volume: 152 start-page: 790 year: 2012 end-page: 793 article-title: Bone marrow‐derived stromal cell therapy for traumatic brain injury is neuroprotective via stimulation of non‐neurologic organ systems publication-title: Surgery – volume: 6 start-page: e21703 year: 2011 article-title: Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses publication-title: PLoS One – volume: 225 start-page: 341 year: 2010 end-page: 352 article-title: Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: Preserving the blood brain barrier via an interaction with splenocytes publication-title: Exp Neurol – volume: 35 start-page: 1416 year: 2017 end-page: 1430 article-title: Prostaglandin E2 indicates therapeutic efficacy of mesenchymal stem cells in experimental traumatic brain injury publication-title: Stem Cells – volume: 8 start-page: 795 year: 2017 article-title: Safety and side effects of using placenta‐derived decidual stromal cells for graft‐versus‐host disease and hemorrhagic cystitis publication-title: Front Immunol – volume: 27 start-page: 3 year: 1997 end-page: 9 article-title: The cytokine‐mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia publication-title: Eur J Clin Invest – volume: 30 start-page: 896 year: 2002 end-page: 904 article-title: Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain publication-title: Exp Hematol – volume: 83 start-page: 381 year: 2017 end-page: 387 article-title: Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: A prospective cohort study publication-title: J Trauma Acute Care Surg – volume: 30 start-page: 1565 year: 2012 end-page: 1574 article-title: Are therapeutic human mesenchymal stromal cells compatible with human blood? publication-title: Stem Cells – volume: 7 start-page: e42819 year: 2012 article-title: Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity publication-title: PLoS One – volume: 33 start-page: 2726 year: 2015 end-page: 2737 article-title: Bone marrow‐derived mesenchymal stem cells have innate procoagulant activity and cause microvascular obstruction following intracoronary delivery: Amelioration by antithrombin therapy publication-title: Stem Cells – volume: 66 start-page: 1509 year: 2009 end-page: 1515 article-title: Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic‐dose enoxaparin in critically ill patients publication-title: J Trauma – volume: 24 start-page: 2269 year: 2015 end-page: 2279 article-title: Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua publication-title: Stem Cells Dev – volume: 6 start-page: e25171 year: 2011 ident: 2022022809002138600_sct312341-bib-0003 article-title: Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock publication-title: PLoS One doi: 10.1371/journal.pone.0025171 – volume: 83 start-page: 381 year: 2017 ident: 2022022809002138600_sct312341-bib-0026 article-title: Thrombin generation profiles as predictors of symptomatic venous thromboembolism after trauma: A prospective cohort study publication-title: J Trauma Acute Care Surg doi: 10.1097/TA.0000000000001466 – volume: 4 start-page: 17 year: 2009 ident: 2022022809002138600_sct312341-bib-0015 article-title: Global characterization and genomic stability of human multistem, a multipotent adult progenitor cell publication-title: J Stem Cells – volume: 10 start-page: 194 year: 2015 ident: 2022022809002138600_sct312341-bib-0023 article-title: Thromboelastography in patients with acute ischemic stroke publication-title: Int J Stroke doi: 10.1111/j.1747-4949.2012.00919.x – volume: 27 start-page: 3 year: 1997 ident: 2022022809002138600_sct312341-bib-0031 article-title: The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia publication-title: Eur J Clin Invest doi: 10.1046/j.1365-2362.1997.570614.x – volume: 83 start-page: S164 year: 2017 ident: 2022022809002138600_sct312341-bib-0009 article-title: Pro-coagulant activity of human mesenchymal stem cells publication-title: J Trauma Acute Care Surg doi: 10.1097/TA.0000000000001485 – volume: 29 start-page: 871 year: 2011 ident: 2022022809002138600_sct312341-bib-0013 article-title: Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions publication-title: Stem Cells doi: 10.1002/stem.633 – volume: 66 start-page: 529 year: 1991 ident: 2022022809002138600_sct312341-bib-0018 article-title: An anti-tissue factor monoclonal antibody which inhibits TF.VIIa complex is a potent anticoagulant in plasma publication-title: Thromb Haemost doi: 10.1055/s-0038-1646454 – volume: 6 start-page: e21703 year: 2011 ident: 2022022809002138600_sct312341-bib-0028 article-title: Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses publication-title: PLoS One doi: 10.1371/journal.pone.0021703 – volume: 33 start-page: 2726 year: 2015 ident: 2022022809002138600_sct312341-bib-0010 article-title: Bone marrow-derived mesenchymal stem cells have innate procoagulant activity and cause microvascular obstruction following intracoronary delivery: Amelioration by antithrombin therapy publication-title: Stem Cells doi: 10.1002/stem.2050 – volume: 7 start-page: 106 year: 2017 ident: 2022022809002138600_sct312341-bib-0020 article-title: Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy publication-title: Theranostics doi: 10.7150/thno.16911 – volume: 24 start-page: 2269 year: 2015 ident: 2022022809002138600_sct312341-bib-0007 article-title: Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua publication-title: Stem Cells Dev doi: 10.1089/scd.2015.0120 – volume: 30 start-page: 1565 year: 2012 ident: 2022022809002138600_sct312341-bib-0008 article-title: Are therapeutic human mesenchymal stromal cells compatible with human blood? publication-title: Stem Cells doi: 10.1002/stem.1111 – volume: 75 start-page: 37 year: 2013 ident: 2022022809002138600_sct312341-bib-0024 article-title: Hypercoagulability after burn injury publication-title: J Trauma Acute Care Surg doi: 10.1097/TA.0b013e3182984911 – volume: 4 start-page: e7809 year: 2009 ident: 2022022809002138600_sct312341-bib-0016 article-title: Epigenetic signatures associated with different levels of differentiation potential in human stem cells publication-title: PLoS One doi: 10.1371/journal.pone.0007809 – volume: 30 start-page: 896 year: 2002 ident: 2022022809002138600_sct312341-bib-0017 article-title: Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain publication-title: Exp Hematol doi: 10.1016/S0301-472X(02)00869-X – volume: 32 start-page: 2430 year: 2014 ident: 2022022809002138600_sct312341-bib-0029 article-title: Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? publication-title: Stem Cells doi: 10.1002/stem.1729 – volume: 435 start-page: 574 year: 2013 ident: 2022022809002138600_sct312341-bib-0032 article-title: Impact of mesenchymal stem cell secreted PAI-1 on colon cancer cell migration and proliferation publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2013.05.013 – volume: 18 start-page: 683 year: 2009 ident: 2022022809002138600_sct312341-bib-0012 article-title: Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect publication-title: Stem Cells Dev doi: 10.1089/scd.2008.0253 – volume: 35 start-page: 1416 year: 2017 ident: 2022022809002138600_sct312341-bib-0011 article-title: Prostaglandin E2 indicates therapeutic efficacy of mesenchymal stem cells in experimental traumatic brain injury publication-title: Stem Cells doi: 10.1002/stem.2603 – volume: 290 start-page: 1779 year: 2000 ident: 2022022809002138600_sct312341-bib-0004 article-title: Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow publication-title: Science doi: 10.1126/science.290.5497.1779 – volume: 7 start-page: e42819 year: 2012 ident: 2022022809002138600_sct312341-bib-0019 article-title: Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity publication-title: PLoS One doi: 10.1371/journal.pone.0042819 – volume: 8 start-page: 795 year: 2017 ident: 2022022809002138600_sct312341-bib-0021 article-title: Safety and side effects of using placenta-derived decidual stromal cells for graft-versus-host disease and hemorrhagic cystitis publication-title: Front Immunol doi: 10.3389/fimmu.2017.00795 – volume: 18 start-page: 549 year: 2014 ident: 2022022809002138600_sct312341-bib-0025 article-title: Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery publication-title: Crit Care doi: 10.1186/s13054-014-0549-2 – volume: 66 start-page: 1509 year: 2009 ident: 2022022809002138600_sct312341-bib-0022 article-title: Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients publication-title: J Trauma – volume: 100 start-page: 1781 year: 2005 ident: 2022022809002138600_sct312341-bib-0027 article-title: The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography publication-title: Anesth Analg doi: 10.1213/01.ANE.0000149902.73689.64 – volume: 2 start-page: 745 year: 2013 ident: 2022022809002138600_sct312341-bib-0014 article-title: Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis publication-title: Stem Cells Translational Medicine doi: 10.5966/sctm.2013-0031 – volume: 134 start-page: 1087 year: 1989 ident: 2022022809002138600_sct312341-bib-0001 article-title: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis publication-title: Am J Pathol – volume: 152 start-page: 790 year: 2012 ident: 2022022809002138600_sct312341-bib-0006 article-title: Bone marrow-derived stromal cell therapy for traumatic brain injury is neuroprotective via stimulation of non-neurologic organ systems publication-title: Surgery doi: 10.1016/j.surg.2012.06.006 – volume: 225 start-page: 341 year: 2010 ident: 2022022809002138600_sct312341-bib-0002 article-title: Intravenous multipotent adult progenitor cell therapy for traumatic brain injury: Preserving the blood brain barrier via an interaction with splenocytes publication-title: Exp Neurol doi: 10.1016/j.expneurol.2010.07.005 – volume: 8 start-page: 223 year: 2011 ident: 2022022809002138600_sct312341-bib-0005 article-title: Stem cells and cell therapies in lung biology and lung diseases publication-title: Proc Am Thorac Soc doi: 10.1513/pats.201012-071DW – volume: 388 start-page: 175 year: 1994 ident: 2022022809002138600_sct312341-bib-0030 article-title: Studies on the inflammatory-coagulant axis in the baboon response to E. coli: Regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor publication-title: Prog Clin Biol Res |
| SSID | ssj0000696920 |
| Score | 2.3998218 |
| Snippet | Clinical cellular therapeutics (CCTs) have shown preliminary efficacy in reducing inflammation after trauma, preserving cardiac function after myocardial... |
| SourceID | pubmedcentral proquest gale pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 731 |
| SubjectTerms | Adipose Tissue - cytology Amniotic fluid Amniotic Fluid - cytology Biotechnology industry Blocking antibodies Blood Coagulation Bone marrow Bone Marrow Cells - cytology Bone marrow transplantation Cell lines Cell- and Tissue-Based Therapy - methods Cerebral infarction Clinical cellular therapeutics Clinical trials Clotting Coagulation Enabling Technologies for Cell‐Based Clinical Translation Ethylenediaminetetraacetic acid Experiments Fetal Blood - cytology Flow cytometry Good Manufacturing Practice Heart attack Heart attacks Humans Leukocytes (mononuclear) Mesenchymal Stem Cells - cytology Mesenchymal Stem Cells - metabolism Myocardial infarction Phenotypes Progenitor cells Recovery of function Scientific equipment and supplies industry Stem cells Thrombelastography Thrombin Thrombin - metabolism Thromboplastin - genetics Thromboplastin - metabolism Tissue factor Translational s and Reviews Trauma Umbilical cord |
| SummonAdditionalLinks | – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA66XryI4qu-qKAnrbZ5NO1xWVwWQRHchb2FJk1QqF1x1__vTNvtPkDBc6ahmclkvgmTbwi5ks7kkCWIgFsOCYplNEg1lUEoqHHM6TS2-Dj56TkejPjjWIybCzd8C1PzQ7QXbugZ1XmNDp7p6f2CNHRqZh93URJg1N8kW4DrGe5wyl_aO5YwTuO0YmaEwCYDgC68qX2HKe6XJ1iJSutn81JwWi-cXAa0VUTq75KdBkr63dr2e2TDlvskaYg-C79niwJrTP3h4onV1O8aA4EG-SH8XjGZ-f3548UDMuo_DHuDoOmOEBiegF5ZbqUWKWSYUSYA97iMJdplRsuEOUcNQAmGTCsiCXMnqLYSVB9DeuViIw3T7JB0yklpj4mvJc3y0IRO5hjQYVJNIyYyQ3WeOpd75GauHWUa6nDsYFGomvSYKtSlihKskBMeuW6lP2vKjF_kzlDRCj0JZjOwr43qSgYZEE9jDsNzA6jGr6aKwpp4hN22PHLZDuOXWCtW2sk3yCCqSSHzApmj2l7tfzCkNwLU5RG5YslWANm2V0fK97eKdRsbCwDW88htZfM_l6Zee0MGmIBHJ_8TPyXbgMhqwt3ojHRmX9_2HFDPTF9UW_sHdfP7OQ priority: 102 providerName: Wiley-Blackwell |
| Title | Clinical Cellular Therapeutics Accelerate Clot Formation |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fsctm.18-0015 https://www.ncbi.nlm.nih.gov/pubmed/30070065 https://www.proquest.com/docview/2331417316 https://www.proquest.com/docview/2082095506 https://pubmed.ncbi.nlm.nih.gov/PMC6186273 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7RVkhcEG8CZRUkOEFo_IqTE1pWXVVIVBVspb1ZsWOrSCFb2O2Bf89M4k27lejZEyvx2DPfTMbfALzTwTUYJahMeokBihc8qyzXWa64CyLYqvB0OfnbaXFyLr8u1TIm3NaxrHJrE3tD3awc5ciPuBBMMuqz9Pnyd0Zdo-jvamyhsQcHDJEItW7QSz3mWPKiKqqemREdm84QushY-4524GjtNr8-sTIj2LDjlW7b5hvO6Xbh5E1A23uk-SN4GKFkOh10_xju-e4J3B-aS_59CmWk_GzTmW9bqjZNF9eXrdbp1Dl0OcQUkc7a1Sadb68xPoPz-fFidpLFPgmZkyWusGi8tqrCWJPVChFQqEVpQ-2sLkUI3CGoEMS5osq8CYpbr1EJBQZaoXDaCSuew3636vxLSK3mdZO7POiGXDtOajkTqnbcNlUITQIftutkXCQRp14WrRnoj7mhVTWspFo5lcD7UfpyIM_4j9whLbmhM4WzOdzhzky1wFhIVoXE4a0qTDxha3O9HxJ4Ow7Tk1Q11vnVFcoQvqkwBkOZF4PmxvcQRHSE-CsBvaPTUYB4t3dHup8XPf82tRhA1JfAx177d36a-TFbCEQHkr26-ytewwPEYgPVLjuE_c2fK_8G8c7GTmCPy7NJv7UncPDl-PTs-6TPHfwDpt__VA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrRBcEG8CLQSJniA0sZ04OVRou3S1pe0KwVbqzcSOLZBCtrBbof45fhszebVbid569sSyPbbnG2fmG4A30pkCvYQ4EFagg2I5CzLNZBDGzDjudJZYSk4-miaTY_HpJD5Zg79dLgyFVXZ3Yn1RF3NDb-TbjPNIRFRn6cPpr4CqRtHf1a6ERt6WVih2aoqxNrHjwJ7_QRdusbP_EfW9xdh4bzaaBG2VgcCIFMfHCyt1nKGnFuUxfuxynmqXGy1T7hwzaJI5MZbEaVi4mGkrcQoJuikuMdJwzbHfW7Au6AFlAOu7e9PPX_pXnjDJkqzmhkTTKgMET6KNvsebaHthlj_fR2lAwGXFLl61DpfM49XQzcuQuraJ4_twrwWz_rDZfQ9gzVYP4XZT3vL8EaQt6Wjpj2xZUryrP7tI91r4Q2PQ6BFXhT8q50t_3CVSPobjG1nDJzCo5pV9Br6WLC9CEzpZELjATjWLeJwbpovMucKDt906KdPSmFM1jVI1BMxM0aqqKKVovdiDrV76tKHv-I_cBi25olONvRk8Y0YNJUdvTGSJwOZOFao94wt1sSM9eN0305cUt1bZ-RnKEMLK0AtEmaeN5vpxcKJaQgTogVzRaS9AzN-rLdWP7zUDOBU5QNzpwbta-9dOTX0dzTjiExE9v34Wr-DOZHZ0qA73pwcv4C4iw4b4N9qAwfL3md1E9LXUL9st7sO3mz5V_wAGxD73 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIhAXxJtAgSDRE4RN_IiTA0KrLauWQoXEVtqbiR1bVEqzhd0K9a_x65jJq91K9NazJ5bt8Xi-ccbfALxR3pYYJchIOIEBiuMsyg1TUSyZ9dybPHX0OPnrQbp7KD7P5XwD_vZvYSitsj8Tm4O6XFi6Ix8xzhORUJ2lke_SIr7tTD-e_IqoghT9ae3LabRbZN-d_cHwbflhbwd1vc3Y9NNssht1FQYiKzIcGy-dMjLHKC0pJGIHX_DM-MIalXHvmUV3zImtRGZx6SUzTuHwUwxRfGqV5YZjvzfgpuJCUNkINVfD_U6c5mnesEKiU1URwibR5d3jGTRa2tXx-ySLCLKsecTLfuGCY7yctHkRTDfecHoP7nYwNhy3--4-bLj6AdxqC1uePYSsoxutwomrKsp0DWfnD72W4dhadHfEUhFOqsUqnPZPKB_B4bWs4GPYrBe1ewqhUawoYxt7VRKswE4NS7gsLDNl7n0ZwNt-nbTtCMypjkalW-plpmlVdZJRnp4MYHuQPmmJO_4jt0VLrsmesTeL1mX1WHGMw0SeCmzuVaE7617q870YwOuhmb6kjLXaLU5RhrBVjvEfyjxpNTeMgxPJEmK_ANSaTgcB4vxeb6mPfjbc31TeABFnAO8a7V85Nf19MuOITETy7OpZvILbaEv6y97B_nO4g5CwZfxNtmBz9fvUvUDYtTIvm_0dwo_rNqh_Rbw8kw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Cellular+Therapeutics+Accelerate+Clot+Formation&rft.jtitle=Stem+cells+translational+medicine&rft.au=George%2C+Mitchell+J&rft.au=Prabhakara%2C+Karthik&rft.au=Toledano-Furman%2C+Naama+E&rft.au=Wang%2C+Yao-Wei&rft.date=2018-10-01&rft.pub=Oxford+University+Press&rft.issn=2157-6580&rft.volume=7&rft.issue=10&rft.spage=731&rft_id=info:doi/10.1002%2Fsctm.18-0015&rft.externalDocID=A735764964 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2157-6564&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2157-6564&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2157-6564&client=summon |